Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pembrolizumab plus chemotherapy versus placebo plus chemotherapy in neoadjuvant and adjuvant treatment of triple-negative breast cancer
MOH_2017-02-27_000180Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) and breast cancer comparing Pembrolizumab arm with Placebo arm (2 arms). Started Feb 2017; status: active, not recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on MOH_2017-02-27_000180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-27_000180.